Aimei Health Technology Co., Ltd. (NASDAQ:AFJK) Sees Large Decrease in Short Interest

Aimei Health Technology Co., Ltd. (NASDAQ:AFJK) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totaling 2,710 shares, a decline of 52.3% from the April 30th total of 5,686 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 2,016 shares, the short-interest ratio is currently 1.3 days.

Aimei Health Technology Stock Up 7.5%

Aimei Health Technology stock opened at $43.00 on Wednesday. Aimei Health Technology has a 52 week low of $6.75 and a 52 week high of $130.37. The company’s 50 day moving average price is $38.93 and its two-hundred day moving average price is $38.81. The stock has a market cap of $136.14 million, a P/E ratio of 238.89 and a beta of 0.23.

Aimei Health Technology (NASDAQ:AFJK) last posted its earnings results on Monday, May 4th. The company reported $0.02 EPS for the quarter.

Hedge Funds Weigh In On Aimei Health Technology

Several hedge funds have recently modified their holdings of AFJK. Berkley W R Corp lifted its position in shares of Aimei Health Technology by 5.9% during the 3rd quarter. Berkley W R Corp now owns 450,655 shares of the company’s stock worth $5,101,000 after buying an additional 25,294 shares in the last quarter. Clear Street Group Inc. bought a new stake in shares of Aimei Health Technology in the 3rd quarter worth approximately $691,000. Quarry LP raised its holdings in shares of Aimei Health Technology by 6.4% in the 3rd quarter. Quarry LP now owns 167,081 shares of the company’s stock worth $1,891,000 after purchasing an additional 10,000 shares during the period. Dakota Wealth Management bought a new stake in shares of Aimei Health Technology in the 4th quarter worth approximately $406,000. Finally, Geode Capital Management LLC bought a new stake in shares of Aimei Health Technology in the 4th quarter worth approximately $413,000. Institutional investors own 45.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of Aimei Health Technology in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

About Aimei Health Technology

Aimei Health Technology Co, Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors. Aimei Health Technology Co, Ltd was incorporated in 2023 and is based in New York, New York.